

## 7. Literaturverzeichnis

1. Amico, S.; Liehn, J.C.; Desoize, B.; Larbre, H.; Deltour, G.; Valeyre, J.:  
Comparison of phosphatase isoenzymes PAP and PSA with bone scan in  
patients with prostate carcinoma.  
Clin Nucl Med 16 (1991), 643-648
2. Aydiner, A.; Topuz, E.; Disci, R.; Yasasever, V.; Dincer, M.; Dincol, K.; Bilge, N.:  
Serum tumor markers for detection of bone metastasis in breast cancer patients.  
Acta Oncol 33 (1994), 181-186
3. Berndt, L.A.; Sieber, E.; Berndt, R.:  
Morbidity and Mortality of malignant neoplasms of the breast.  
Zeitschr Ärztliche Fortbildung 73 (1979), 1123-1129
4. Berruti, A.; Torta, M.; Piovesan, A.; Raucci, C.A.; Orlandi, F.; Panero, A.:  
Biochemical picture of bone metabolism in breast cancer patients with bone  
metastases.  
Anticancer Res 15 (1995), 2871-2876
5. Berruti, A.; Osella, G.; Raucci, C.A.; Roncari, A.; Dogliotti, L.:  
Transient increase in total serum alkaline phosphatase predicts radiological  
response to systemic therapy in breast cancer patients with osteolytic and mixed  
bone metastases.  
Oncology 50 (1993), 218-221
6. Blijlevens, N.M.; Oosterhuis, W.P.; Oosten, H.R.; Mulder, N.H.:  
Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.  
Anticancer Res 15 (1995), 2711-2716
7. Body, J.J.; Dumon, J.C.; Gineyts, E.; Delmas, P.D.:  
Comparative evaluation of markers of bone resorption in patients with breast  
cancer-induced osteolysis before and after bisphosphonate therapy.  
Br J Cancer 75 (1997), 408-412

8. Bohmert, H.; Eiermann, W.; von Hesler, F.W.; Drzeska, W.; Willich, N.; Lindner, H.:  
Interdisziplinäres Vorgehen in der Primärtherapie des Mammakarzinoms.  
In: Schriftenreihe des Tumorzentrum München mit Empfehlungen zur Diagnostik, Therapie und Nachsorge onkologischer Erkrankungen; Tumorzentrum München (1991), 11-28
  
9. Broyn, J.; Froyen, T.:  
Evaluation of routine follow-up after surgery for breast carcinoma.  
Acta Chem Scand 148 (1982), 401-404
  
10. Brule, G.:  
Co-operative clinical study of 178 patients treated with "Novaldex".  
In: The hormonal control of breast cancer.  
Hrsg: Brule, G.  
ICI Pharmaceutical Division Ltd Alderly Park, Macclesfield, Cheshire (1978), 35-39
  
11. Burlina, A.; Rubin, D.; Secchiero, S.; Sciacovelli, L.; Zaninotto, M., Plebani, M.:  
Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase.  
Clin Chem Acta 226 (1994), 151-158
  
12. Caffier, H.; Brandau, H.:  
Serum tumor markers in metastatic breast cancer and course of disease.  
Cancer Detect Prev 6 (1983), 451
  
13. Carey, P.O.; Lippert, M.C.:  
Treatment of painful prostatic bone metastases with oral etidronate disodium.  
J Urol 32 (1988), 403-407

14. Coleman, R.E.; Mashiter, G.; Whitaker, K.B.; Moss, D.W.; Rubens, R.D.; Fogelman, I.:  
Bone scan flare predicts succesful systemic therapy for bone metastases.  
J Nucl Med 29 (1988), 1354-1389
  
15. Coleman, R.E.; Rubens, R.D.:  
Bone metastases and breast cancer.  
Cancer Treat Rev 12 (1985), 251-270
  
16. Coleman, R.E.; Whitaker, K.B.; Moss, D.W.; Mashiter, G.; Fogelman, I.; Rubens, R.D.:  
Biochemical prediction of response of bone metastases to treatment.  
Br J cancer 58 (1988), 205-210
  
17. Cooper, E.H.; Forbes, M.A.; Hancock, A.K.; Parker, D.; Laurence, V.:  
Serum bone alkaline phosphatase and CA 549 in breast cancer with bone metastases.  
Biomed Pharmacother, 46 (1992), 31-36
  
18. Cooper, E.H.; Purves, D.A.; Yerna, M.J.:  
Tandem Ostase - An IRMA for bone alkaline phosphatase evaluated in breast and prostate cancer.  
In: Current tumor diagnosis: applications, clinical relevance, research, trends, cancer of the lung – state and trends in diagnosis and therapy.  
Hrsg: Klapdor, R.  
Zuckerschwerdt München, Bern, Wien, New York, (1994)
  
19. Creutzig, H.:  
Bedeutung der Knochenszintigraphie für die Nachsorge des Mammakarzinoms.  
Deutsche Med Wochenschrift 111 (1986), 1860-1861

20. Crippa, F.; Bombardieri, E.; Seregini, E.; Castellani, M.R.; Gasparini, M.; Maffioli, L.; Pizzichetta, M.; Buraggi, G.L.:  
Single determination of CA 15-3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer.  
J Nucl Med, 36 (1992), 52-55
  
21. Crivellari, D.; Price, K.N.; Hagen, M.; Goldhirsch, A.; Gelber, R.D.; Castiglione, M.; Coates, A. S.; Rudenstam, C.M.; Collins, J.; Lindtner, J.:  
Routine tests during follow-up of patients after primary treatment for operable breast cancer.  
Ann Oncol, 6 (1995), 769-776
  
22. Crombach, G.:  
Überlegungen zum rationellen Einsatz von Tumormarkern beim Mammakarzinom.  
Schweiz Rundsch Med Prax, 87 (1998), 589-594
  
23. Demers L.M.; Costa, L.; Chinchilli, V.M.; Gaydos, L.; Curley, E.; Lipton, A.:  
Biochemical markers of bone turnover in patients with metastatic bone disease.  
Clin Chem 41 (1995), 1489-1494
  
24. De Waard, F.:  
Epidemiology of breast cancer – a review.  
Cancer Clin Oncol 19 (1983), 1671-1676
  
25. Davies, J.; Trask, C.; Souhami, R.L.:  
Effect of mithramycin on widespread painful bone metastases in cancer of the breast.  
Cancer Treat Rep 63 (1979), 1835-1838
  
26. Desoize, B.; Veiler, V.; Pourny, C.; Comoe, L.; Jardillier, J.C.:  
Isoenzymes of alkaline and acid phosphatases as bone metastasis marker in breast cancer patients.  
Anticancer Res 9 (1989), 1105-1109

27. Desoize, B.; Pourny, C.; Amico, S.; Larbre, H.; Jardillier, J.C.:  
Evaluation de deux isoenzymes seriques des phosphatases comme marqueurs  
des metastases osseuses.  
Bull Cancer (Paris) 77 (1991), 1211-1221
  
28. Diel, I.J.; Costa, S.D.; Kaufmann, M.; Schmid, H.; Bastert, G.:  
Systemische Therapie des ossär metastasierten Mammakarzinoms (OMM).  
In: Knochenmetastasen: Pathophysiologie, Diagnostik und Therapie.  
Hrsg.: Wüster, C.; Ziegler, R.  
Zuckerschwerdt, München, Bern, Berlin
  
29. Ebeling, K.; Nischan, P.:  
Mammakarzinom-Epidemiologie und Prävention.  
Zeitschr Ärztliche Fortbildung 85 (1991), 956
  
30. Engel, K.; Schmid, H.; Hanke, J.; Kaufmann, M.; Müller, A.:  
CA 15-3 und CEA als Tumormarker zur Rezidivdiagnostik beim Mammakarzinom.  
Geburtsh Frauenheilk 48 (1988), 309-312
  
31. Fleisch, H.:  
Bisphosphonate bei Knochenerkrankungen.  
H. Huber Verlag, Bern (1997)
  
32. Francini, G.; Montagnani, M.; Petrioli, R.; Paffetti, P.; Marsili, S.; Leone, V.:  
Comparison between CEA, TPA, CA 15/3 and hydroxyproline, alkaline  
phosphatase, whole body retention of <sup>99m</sup>Tc MDP in the follow-up of bone  
metastases in breast cancer.  
Int J Biol Markers 5 (1990), 65-72
  
33. Galasko, C.S.B.:  
Skeletal metastases and mammary cancer.  
Ann R Coll Surg Engl 50 (1972), 3-28

34. Galasko, C.S.B.:  
The pathological basis for skeletal scintigraphy.  
J Bone Joint Surg Br 57-B (1975), 353-359
  
35. Gang, Y.; Adachi, T.; Ohkura, H.; Yamamoto, H.; Mizuguchi, Y.; Abe, K.:  
CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies.  
Gan To Kagaku Ryoho (Jap J Cancer Chemother) 12 (1985), 2379-2386
  
36. Gerber, B.; Wilken, H.:  
Nachsorge beim Mammakarzinom.  
Ärztebl Mecklenburg-Vorpommern 12 (1992), 1250-1258
  
37. Go, V.L.:  
Carcinoembryonales antigen: Clinical application.  
Cancer 37 (1976), 562-566
  
38. Goldenberg, D.M.; Neville, M.; Carter, A.C.:  
CEA (carcinoembryonic antigen): its role as a marker in the management of cancer.  
J Cancer Clin Oncol 101 (1981), 239-242
  
39. Gomez, B.J.; Ardakani, S.; Ju, J.; Jenkins, D.; Cerelli, M.J.; Daniloff, G.Y.; Kung, V.T.:  
Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum.  
Clin Chem 41 (1995), 1560-1566
  
40. Harris, J.; Hellmann, S.:  
Observations on survival curve analysis with particular reference to breast cancer treatment.  
Cancer 57 (1986), 925-928

41. Harris, H.:  
The human alkaline phosphatases: what we know and what we don't know.  
Clin Chim Acta 186 (1989), 133
  
42. Hasert, V.:  
Diagnostische Verfahren zur Ergänzung der Mammographie.  
Z ärztl Fortbild 85 (1991), 1001-1006
  
43. Hayes, F.; Zurawsky, V.R.; Kufe, D.W.:  
Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in  
patients with breast cancer.  
J Clin Oncol 4 (1986), 1542-1550
  
44. Hellriegel, K.P.; Schulz, K.D.:  
Nachsorge bei Mammakarzinom-Patientinnen. Empfehlungen einer Konsensus-  
Tagung, Berlin 23. - 24.02. 1995.  
Oncology 1 (1995), 405-412
  
45. Höffken, K.; Kempf, H.; Miller, A.A.; Miller, B.; Schmidt, C.G.; Faber, P.;  
Kley, H.K.:  
Aminoglutethimide without hydrocortisone in the treatment of postmenopausal  
patients with advanced breast cancer.  
Cancer Treat Rep 70 (1986), 1153-1157
  
46. Hossfeld, K.; Kleeberg, U.R.:  
Gedanken zur Nachsorge bei Patientinnen mit Mammakarzinom.  
Deutsches Ärztebl 90 (1993), 437-439
  
47. Hölzel, D.; Thieme, C.H.:  
Die Skelettszintigraphie in der Nachsorge des Mammakarzinoms. Statistische  
und epidemiologische Gesichtspunkte.  
Deutsche Med Wsch 111 (1986), 1191-1199

48. Hortobagyi, G.N.; Libshitz, H.I.; Seabold, J.E.:  
Osseous metastases of breast cancer. Clinical, biochemical, radiographic and scintigraphic evaluation of response to therapy.  
Cancer 53 (1984), 577-582
  
49. Horton, J.:  
Follow-up of breast cancer patients.  
Cancer 53 (1984), 790-797
  
50. Kamby, C.; Vejborg, I.; Daugard, S.; Guldhammer, B.; Dirksen, H.; Rossing, N.:  
Clinical and radiologic characteristics of bone metastases in breast cancer.  
Cancer 60 (1987), 2524-2531
  
51. Kamby, C.; Egsmose, C.; Söletormos, G.; Dombernowsky, P.:  
The diagnostic and prognostic value of serum bone Gla protein (osteocalcin) in patients with recurrent breast cancer.  
Scand J Clin Lab Invest 53 (1993), 439-446
  
52. Khandekar, J. D.:  
Recommendations on follow-up of breast cancer patients following primary therapy.  
Sem Surg Oncol 12 (1996), 346-351
  
53. Kleist, v. S.:  
Die Rezidiverkennung von Mammakarzinomen mit Hilfe von Tumormarkerbestimmungen.  
In: Aktuelle Aspekte in der Diagnostik des Mammakarzinoms.  
Hrsg: Jonat, W.  
Bücherei des Frauenarztes 31 (1989), 57

54. Kloskowski, S.; Ebeling, K.:  
Nutzen der monatlichen Selbstuntersuchung der Brust für die Früherkennung des Mammakarzinoms.  
Arch Geschwulstforsch 60 (1990), 377-382
  
55. Kreienberg, R.:  
Allgemeine und spezifische Laborparameter im Rahmen der Tumornachsorge bei gynäkologischen Malignomen und bei Mammakarzinomen.  
Gynäkologe 22 (1989), 55-62
  
56. Lamerz, R.; Fateh-Moghadam, A.:  
Carcinofetale Antigen. II. Carcinoembryonales Antigen (CEA).  
Klin Wochenschr 53 (1975), 193-203
  
57. Langlands, A.; Pocock, S.; Kerr, G.; Gore, S.M.:  
Long-term survival of patients with breast cancer: a study of the curability of the disease.  
Br Med J 2 (1979), 1247-1251
  
58. Leonhardt, A.:  
Konzeption der programmierten und standardisierten Mammakarzinom-Nachsorge.  
Münch Med Wochenschr 118 (1976), 297-302
  
59. Lerner, H.J.; Band, P.R.; Israel, L.; Leung, B.S.:  
Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer.  
Cancer Treat Rep 60 (1976), 1431-1435
  
60. Liberati, A.:  
The GIVIO trial on the impact of follow-up care on survival and quality of life in breast cancer patients.  
Ann Oncol 6 (1995), 41-46,

61. Loprinzi, C.L.; Ahmann, D.L.:  
Carcinoembryonic antigen. A routine test in patients with breast carcinoma ?  
Arch Int Med 146 (1986), 2125-2126
  
62. Lorente, J.A.; Morote, J.:  
Behavior of bone alkaline phosphatase (BAP) determined with  
immunoradiometric assay in metastatic prostate cancer.  
Int J Biol Markers 9 (1994), 145
  
63. Mackintosh, J.; Simes, J.; Raghavan, D.; Pearson, B.:  
Prostatic cancer with bone metastases: serum alkaline phosphatase (SAP) as a  
predictor of response and the significance of the SAP "flare".  
Br J Urol 66 (1990), 88-93
  
64. Marchai, P.; Santini, D.; Bianco, V.; Chiodini, S.; Reale, M. G.; Simeoni, F.;  
Marchei, G. G.; Vecchione, A.:  
Serum ostease in the follow-up of breast cancer patients.  
Anticancer Res 15 (1995), 2217-2222
  
65. Martinetti, A.; Bajetta, E.; Seregni, E.; Zilembo, N.; Ferrari, L.; Noberasco, C.;  
Massaron, S.; Rimassa, L.; Bombardieri, E.:  
Serum markers of bone metastases in postmenopausal breast cancer patients  
treated with formestane.  
Tumour Biol 18 (1997), 197-205
  
66. Mayne, P.D.; Thakar, S.; Rosalki, S.B.; Foo, A.Y.; Parbhoo, S.:  
Identification of bone and liver metastases from breast cancer by measurement of  
plasma alkaline phosphatase isoenzyme activity.  
J Clin Pathol 40 (1987), 398-403
  
67. Mc Comb, R.B.; Bowers, G.N.; Posen, S.:  
Alkaline Phosphatase.  
Plenum Press, New York, (1979)

68. Miller, A.B.; Bulbrook, R.D.:  
UICC multidisciplinary project on breast cancer: The epidemiology, aetiology and prevention of breast cancer.  
Int J Cancer 37 (1986), 173-177
69. Möbus, V.; Kreienberg, R.:  
Aktuelle Tumormarker beim Mammakarzinom.  
In: Aktuelle Aspekte in der Diagnostik des Mammakarzinoms.  
Hrsg: Jonat, W.  
Bücherei des Frauenarztes 31 (1989), 62
70. Montravers, F.; Younsi, N.; Rousseau, C.; Philippe, C.; Seddiki, M.; Uzan, S.; Izrael, V.; Talbot, JN:  
Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.  
Anticancer Res 17 (1997), 1683-1686
71. Murray, R.M.; Pitt, P.:  
Medical adrenalectomy in patient with advanced breast cancer resistant to anti-oestrogen treatment.  
Breast Cancer Res Treat 1 (1981), 91-95
72. Oremek, G.M.; Kramer, W.; Seiffert, U.B.; Jonas, D.:  
Diagnostic value of skeletal AP and PSA with respect to skeletal scintigram in patients with prostatic disease.  
Anticancer Res 17 (1997), 3035-3036
73. O'Mara, R.E.:  
Skeletal scanning in neoplastic disease.  
Cancer 37 (1976), 480-486
74. Ormiston, M. C.; Timoney, A. G.; Qureshi, A. R.:  
Is follow up of patients after surgery for breast cancer worthwhile?  
J R Soc Med 78 (1985), 920-921

75. Pandya, K.J.; Mc Fadden, E.T.; Kalish, L.A.; Tormey, D.C.; Taylor, S.G.; Falkson, G.:  
A retrospective study of earliest indicators of recurrence in patients on Eastern Cooperative Oncology Group Adjuvant Chemotherapy Trials for breast cancer. A preliminary report.  
Cancer 55 (1985), 202-205
76. Panigrahi, K.; Delmas, P.D.; Singer, F.; Ryan, W.; Reiss, O.; Fisher, R.; Miller, P.D.; Mizrahi, I.; Darte, C.; Kress, B.C.:  
Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum.  
Clin Chem 40 (1994), 822-828
77. Paterson, C.R.; Robins, S.P.; Horobin, J.M.; Preece, P.E.; Cuschieri, A.:  
Pyridinium crosslinks as markers of bone resorption in patients with breast cancer.  
Br J Cancer 64 (1991), 884-886
78. Paulick, R.; Caffier, H.:  
Klinische Bedeutung erhöhter CEA-Werte in der Nachsorge von Patientinnen mit Mammakarzinom.  
Geburtsh Frauenheilk 45 (1985), 774-779
79. Paulick, R.; Caffier, H.; Paulick, M.:  
Comparison of serum CEA, PHI, and TPA as tumor markers in breast cancer patients.  
Cancer Detect Prev 10 (1987), 197-203
80. Pedrazzini, A.; Gelber, R.; Isley, M.; Castiglione, M.; Goldhirsch, A.:  
First repeated bone scan in the observation of patients with operable breast cancer.  
J Clin Oncol 4 (1986), 389-394

81. Perez, D.J.; Powles T.J.; Milan, J.; Gazet, J.C.; Ford, H.T.; Mc Cready, V.R.:  
Detection of breast carcinoma metastases in bone: relative merits of X-rays and  
skeletal scintigraphy.  
Lancet 2 (1983), 613-616
  
82. Piovesan, A.; Berruti, A.; Torta, M.; Cannone, R.; Sperone, P.; Panero, A.;  
Gorzegno, G.; Termine, A.; Dogliotti, L.; Angeli, A.:  
Comparison of assay of total and bone-specific alkaline phosphatase in the  
assessment of osteoblast activity in patients with metastatic disease.  
Calcif Tissue Int 61 (1997), 362-369
  
83. Plebani, M.; Bernadi, D.; Zaninotto, M.; de Paoli, M.; Secchiero, S.; Sciacovelli, L.:  
New and traditional serum markers of bone metabolism in the detection of  
skeletal metastases.  
Clin Biochem 29 (1996), 67-72
  
84. Possinger, K.; Wilmanns, W.:  
Palliative Therapieführung zur Hemmung der Tumorprogression bei Patientinnen  
mit metastasierten Mammakarzinomen.  
Internist (1993) 34: 340-350
  
85. Powels, T.J.:  
Advanced breast cancer-new approaches to treatment: a review.  
Eur J Cancer Clin Oncol 21 (1988): 95-98
  
86. Preiss, J; Dornoff, W.; Hagmann, F.G.; Schmieder, A.:  
Mammakarzinom.  
In: Empfehlungen zur Therapie.  
Hrsg.: Onkologische Arbeitsgemeinschaft Saar-Pfalz-Mosel-e.V.  
Onkologie 1998/99 (1998), 127-132

87. Reale, M.G.; Santini, D.; Marchei, G.G.; Manna, A.; Del Nero, A.; Marchei, P.:  
Skeletal alkaline phosphatase as a serum marker of bone metastases in the  
follow-up of patients with breast cancer.  
Int J Biol Markers 10 (1995), 42-46
88. Rieden, K.:  
Knochenmetastasen: Radiologische Diagnostik, Therapie und Nachsorge.  
Springer-Verlag, Berlin, Heidelberg, New York, London, Tokyo, (1988)
89. Reitzig, P.:  
Tumornachsorge beim Mammakarzinom-was ist sinnvoll.  
Zeitschr Ärztl Fortbild 85 (1991), 1053
90. Roselli Del Turco, M.; Palli, D.; Cariddi, A.; Ciatto, S.; Pacini, P.; Distante, V.:  
Intensive diagnostic follow-up after treatment of primary breast cancer.  
JAMA 271 (1994), 1593-1597
91. Rosen, P.; Groshen, W.; Saigo, P.; Kinne, D.W.; Hellman, S.:  
A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0)  
breast carcinoma.  
J Clin Oncol 7 (1989), 355-366
92. Rubens, R.D.; Fogelman, I.:  
Bone metastases: diagnosis and treatment.  
Springer, Berlin, Heidelberg, New York, London, Tokyo, (1991)
93. Rühl, U.:  
Die Strahlentherapie nach Radikaloperation-Indikationen-Technik-  
Komplikationen.  
Z ärztl Fortbild 85 (1991), 1045-1046
94. Rutgers, E.J.; van Slooten, E.A.; Kluck, H.M.:  
Follow-up after treatment of primary breast cancer.  
Br J Surg 76 (1989), 187-190

95. Scanlon, E.F.; Oviedo, M.A.; Cunningham, M.P.; Caprini, J.A.; Khandekar, J.D.:  
Preoperative and follow-up procedures on patients with breast cancer.  
Cancer 46 (1980), 977-979
96. Schapira, D.V.; Urban, N.:  
A minimalist policy for breast cancer surveillance.  
JAMA 265 (1991), 380-382
97. Schatz, C.; Lieven, H.V.; Mulders, M.; Rowold, J.; Stracke, H.; Müller, H.; Grebe, S.F.; Schatz, H.:  
Die Tumormarker CEA, TPA, und CA 19-9 sowie Ferritin und Osteocalcin in der Verlaufskontrolle beim Mammakarzinom.  
Wien Klin Wochenschr 23 (1985), 873-879
98. Schmid, L.; Schröck, R.; Langhammer, C.; Hünichen, A.; Bryxi, V.; Oberdorfer, M.:  
CA 15-3 und CEA in der Verlaufskontrolle des chemo-/hormontherapierten metastasierten Mammakarzinoms.  
In: Klinische Relevanz neuer monoklonaler Antikörper: 3. Hamburger Symposium über Tumormarker (1985).  
Hrsg: Greten, H. und Klapdor, R.  
Thieme, Stuttgart, (1986)
99. Schmidt-Rhode, P.; Rück, A.; Schulz, K. D.:  
Nachsorge des Mammakarzinoms.  
In: Gynäkologische Onkologie: Diagnostik, Therapie und Nachsorge bei Mamma- und Genital-Karzinomen in der Praxis.  
Hrsg: Mallmann, P. und Krebs, D.  
Zuckerschwerdt, München, Bern, Wien, New York, (1995), 195-205

100. Schreiber, R.R.:  
The radiologist and the diagnosis of bone metastasis.  
In: Bone Metastasis.  
Hrsg: Weiss, L.; Gilbert, H.A.; Hall, G.K.  
Medical publishers, Boston, (1981)
  
101. Schünemann, H.; Jourdain, M.:  
Stellenwert der Skelettszintigraphie in der Nachsorge des Mammakarzinoms.  
Deutsche Med Wochenschrift 114 (1989), 3-8
  
102. Schumacher, T.; Schmitz, S.; Diehl, V.:  
Prognoserelevanz der onkologischen Nachsorge.  
Versicherungsmedizin 47 (1995), 166-170
  
103. Seifert, M.; Adler, A.; Obermair, A.; Hartmann, B.; Denison, U.; Kubista, E.;  
Sevelde, P.:  
Möglichkeiten und Ziele in der Tumornachsorge beim Mammakarzinom.  
Gynakol Rundsch 31 (1991), 309-311
  
104. Sekine, H.; Hayes, D.F.; Ohno, T.; Keefe, K.A.; Schaetzel, E.; Bast, R.C.;  
Knapp, R.:  
Circulating DF3 and CA 12-5 antigen levels in serum from patients with epithelial  
ovarian carcinoma.  
J Clin Oncol 3 (1985), 1355-1363
  
105. Shinozaki, T.; Chigira, M.; Kato, K.:  
Multivariate analysis of serum tumor markers for diagnosis of skeletal  
metastases.  
Cancer 69 (1992), 108-112

106. Spiessl, B.; Beahrs, O.H.; Hermanek, P.; Hutter, R.V.P.; Scheibe, O.; Sobin, L.H.; Wagner, G.:  
Mammatumoren.  
In: TNM-Atlas. Illustrierter Leitfaden zur TNM/pTNM-Klassifikation maligner Tumoren.  
Springer, Berlin, Heidelberg, New York, London, Tokyo, (1993)
- 107.. Stegner, H.E.:  
Gynäkologie und Geburtshilfe.  
Enke, (1996)
108. Stieber, P.; Nagel, D.; Ritzke, C.; Rössler, N.; Kirsch, C.M.; Eiermann, W.; Fateh-Moghadam, A.:  
Significance of bone alkaline phosphatase, CA 15-3 and CEA in the detection of bone metastases during the follow-up of patients suffering from breast carcinoma.  
Eur J Clin Chem Clin Biochem 30 (1992), 809-814
109. Smalley, R.V.; Scogna, D.M.; Malmud, L.S.:  
Advanced breast cancer with bone-only metastases. A chemotherapeutically responsive pattern of metastases.  
Am J Clin Oncol 5 (1982) 161-166
110. The GIVIO Investigators:  
Impact of follow-up and testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized trial.  
JAMA 272 (1994), 1587-1592
111. Theriault, R.L.; Hortobagyi, G.N.:  
Bone metastases in breast cancer.  
Anticancer Drugs 3 (1992), 455-462

112. Tobias, R.; Rithwell, C.; Wagner, J.; Green, A.; Liu, Y.S.V.:  
Development and evaluation of a radioimmunoassay for the detection of a monoclonal antibody defined breast tumor associated antigen 115D8/DF3.  
Kongress der American Association of Clinical Chemistry (AACC), (Atlanta 1985)
113. Tomin, R.; Donegan, W.:  
Screening for recurrent breast cancer - its effectiveness and prognostic value.  
J Clin Oncol 5 (1987), 62-67
114. Tondini, C.; Hayes, D.F.; Gelmann, R.; Henderson, I.C.; Kufe, D.W.:  
Comparison of CA 15-3 and CEA in monitoring the clinical course of patients with metastatic breast cancer.  
Cancer Res 48 (1988), 4107-4112
115. Umbach, G.E.; Holzki, C.; Perschman, U.; Schnurch, H.G.; Bender, H.G.:  
Erfahrungen in der Nachsorge von Patientinnen mit Mammakarzinom.  
Geburtsh Frauenheilk 48 (1988), 292-298
116. van Dalen, A.:  
TPS in breast cancer-a comparative study with carcinoembryonic antigen and CA 15-3.  
Tumour Biol 13 (1992), 10-17
117. van Holten-Verzantvoort, A.T.; Bijvoet Olm Hermans, J.; Cleton, F.J.; Krohn, H.M.; Harinck, H.I.; Vermey, P.; Elte, J.W.; Neyt, J.P.; Beex, L.V.:  
Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment.  
Lancet 2 (1987), 983-985
118. Wandt, H.; Brunsch, U.; Gallmeier, W.M.:  
Nachsorge beim Mammakarzinom.  
Deutsche Med Wochenschrift 114 (1989), 1130-1136

119. Webber, W.; Boyd, N.:  
A critique of the methodology of studies of benign breast disease and breast cancer risk.  
J Nat Cancer Inst 77 (1986), 397-404
  
120. Weiss, M.; Cole, D.; Ray, K.; Whyte, M.P.; Lafferty, M.A.; Mulivor, R.A.; Harris, H.:  
A missense mutation in the human liver-bone-kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia.  
Proc Natl Acad Scie U S A 85 (1988), 7666-7669
  
121. Wertheimer, M.D.:  
Against minimalism in breast cancer follow-up.  
JAMA 265 (1991), 396-397
  
122. Westerhuis, L. W.; Delaere, K. P.:  
Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer.  
Eur J Clin Chem Clin Biochem 35 (1997), 89-94
  
123. Winchester, D.P.; Sener, S.F.; Khandekar, J. D.; Oviedo, M.A.; Cunningham, M.P.; Caprini, J.A.; Burkett, F.E.; Scanlon, E.F.:  
Symptomatology as an indicator of recurrent or metastatic breast cancer.  
Cancer 43 (1979), 956-960
  
124. Winzer, J.W.:  
Die chirurgische Therapie beim nichtinvasiven Karzinom der Mamma.  
Z ärztl Fortbild 85 (1991), 1041-1044
  
125. Withold, W.; Gorgescu, G.; Khakzad, H.; Vosberg, H.; Mueller-Gaertner, H.W.; Reinauer, H.:  
Efficiency of simultaneous determination of bone alkaline phosphatase mass concentration in serum and urinary excretion of pyridinium cross-links for detection of bone metastases.  
Clin Biochem 28 (1995), 511-517

126. Wolff, J. M.; Ittel, T.; Boeckmann, W.; Reinike, T.; Habib, F. K.; Jaske, G.:  
Skeletal alkaline phosphatase in the metastatic workup of patients with prostate cancer.  
Eur Urol 30 (1996), 302-306
  
127. Yamashita, K.; Ueda, T.; Takafumi, U.; Komatsubara, Y.; Koyama, H.; Inaji, H.; Yonenobu, K.; Ono, K.:  
Breast cancer with bone-only metastases. Visceral metastases-free rate in relation to anatomic distribution of bone metastases.  
Cancer 68 (1991), 634-637
  
128. Zanco, P.; Rota, G.; Sportiello, V.; Borsato, N.; Ferlin, G.:  
Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques.  
Int J Biol Markers 4 (1989), 103-105
  
129. Zaninotto, M.; Secchiero, S.; Rubin, D.; Sciacovelli, L.; Trovo, M.; Bortolus, R.; Plebani, M.:  
Serum bone alkaline phosphatase in the follow-up of skeletal metastases.  
Anticancer Res 15 (1995), 2223-2228
  
130. Zwaveling, A.; Albers, G.H.; Felthuis, W.; Cronin, W.:  
An evaluation of routine follow-up for detection of breast cancer recurrences.  
J Surg Oncol 34 (1987), 194-197